Evaluation of Endothelial Dysfunction Using the "Flow Mediated Dilation" Test in a Population of Chronic Renal Failure Patients at Different Stages, and Evaluation of the Role of Antiphospholipid Antibodies

Launched by BRUGMANN UNIVERSITY HOSPITAL · Apr 2, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well blood vessels are functioning in patients with chronic kidney disease (CKD) and the potential impact of certain antibodies called antiphospholipid antibodies (aPL). It aims to understand if these antibodies, which can lead to blood clotting issues, are linked to problems with blood flow in patients undergoing hemodialysis—a treatment that helps remove waste from the blood when the kidneys aren’t working properly. The study will use a test called the "flow mediated dilation" (FMD) test to assess blood vessel function and compare results among different stages of CKD and with healthy individuals.

Patients aged 65 to 74 with chronic kidney disease from stages G3a to G5 may be eligible to participate, along with healthy volunteers. Participants can expect to undergo the FMD test, which is a simple procedure that measures how well their blood vessels can expand and improve blood flow. The study will also look at how factors like the timing between dialysis sessions and the presence of aPL antibodies relate to blood vessel health. This research could help improve the understanding of cardiovascular risks in dialysis patients and guide better care strategies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with Chronic kidney disease from stage G3a to G5
• • Healthy volunteers
• Exclusion Criteria:
• • Patients with chronic kidney disease stage G5 with no dosage available of antiphospholipid antibodies.